Companies envision therapies for up to six targets, combining platforms to create ‘what could be a whole new class of therapeutics”.
AbCellera is partnering with Moderna to develop mRNA-encoded antibody drugs by applying Moderna’s mRNA platform and AbCellera’s AI-based antibody discovery platform. AbCellera’s platform will identify therapeutic antibodies against up to six targets to be selected by Moderna by searching and analyzing natural immune responses. [AbCellera]
Through the partnership, whose value was not disclosed, AbCellera’s platform will identify therapeutic antibodies against up to six targets—to be selected by Moderna—by searching and analyzing natural immune responses. Moderna and AbCellera are not disclosing which therapeutic areas the antibodies will address. “What I can say is that it's not a collaboration that's restricted to infectious disease,” AbCellera CEO and co-founder Carl Hansen, PhD, told GEN Edge . . .
